Effectiveness of Albumin for Liver Cirrhosis and Bacterial Infections: A Review
Human albumin infusions administered alongside antibiotics to patients with cirrhosis and bacterial infections show very uncertain clinical benefits regarding survival, kidney damage, and complication rates, according to a systematic review updated on August 20, 2025. Cirrhosis, a progressive condition characterized by severe liver scarring, routinely triggers systemic complications such as ascites, hepatic encephalopathy, and jaundice.
Key Clinical Takeaways:
- Current clinical evidence remains very uncertain regarding whether albumin reduces mortality, serious adverse events, or septic shock in patients with cirrhosis and bacterial infections.
- Data from 11 randomized studies involving 1,273 adult participants show that findings are limited by methodological flaws and insufficient trial designs.
Evaluating Albumin Versus No Intervention in Clinical Trials
Researchers evaluating the efficacy of human albumin compared against no intervention face significant data gaps. According to the systematic review analyzing 11 trials with 1,273 adult participants averaging 54 years of age, investigators cannot definitively determine whether albumin alters all-cause mortality or severe complications. Out of the evaluated studies, eight examined albumin against no treatment, while three compared the protein solution directly against alternative intravenous fluids like saline or synthetic colloids. Five of these trials focused specifically on spontaneous bacterial peritonitis, an infection of the peritoneal membrane lining the abdominal cavity. Four trials investigated infections across multiple anatomical sites including the lungs, urinary tract, and skin, while two trials enrolled patients suffering from severe infections accompanied by dangerously low blood pressure.
Geographic diversity across the research pool spanned eight European countries alongside clinical sites in India, Spain, China, France, Egypt, and Taiwan. Approximately half of these investigations maintained short-term follow-up periods of up to one month, whereas the remaining half tracked patients for three months. Ten studies reported no for-profit support or operated independently, while one trial declared partial private support involving the delivery of albumin vials. Methodological weaknesses, however, severely constrain these findings. The certainty of evidence across all primary endpoints was rated as low or very low due to poor study design, incomplete follow-up, and inadequate sample sizes lacking pediatric representation.
Contrasting Albumin With Alternative Intravenous Fluids
When stacked against alternative resuscitation fluids such as crystalloids or synthetic colloids, human albumin yields similarly ambiguous outcomes. The review indicates that researchers are very uncertain whether albumin influences mortality or renal protection, or whether it elevates the incidence of serious unwanted events. Furthermore, data regarding septic shock reduction remain inconclusive, and none of the trials systematically captured patient-reported well-being or broader functional recovery metrics. These limitations highlight a persistent clinical challenge in fluid resuscitation protocols for advanced liver disease.
Future research directives must prioritize large-scale, double-blind, randomized controlled trials that blind both participants and investigators to the administered interventions. Experts emphasize that upcoming protocols must also incorporate pediatric cohorts and directly compare distinct formulations of albumin against varied crystalloid and colloid solutions. Maintaining rigorous oversight and individualized risk stratification remains essential for patient safety in this vulnerable population.
*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*